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Abstract
Background: Gel-type autologous chondrocyte (Chondron™) implantations have been used for several years without 
using periosteum or membrane. This study involves evaluations of the clinical results of Chondron™ at many clinical 
centers at various time points during the postoperative patient follow-up.
Methods: Data from 98 patients with articular cartilage injury of the knee joint and who underwent Chondron™ 
implantation at ten Korean hospitals between January 2005 and November 2008, were included and were divided into 
two groups based on the patient follow-up period, i.e. 13~24-month follow-up and greater than 25-month follow-up. 
The telephone Knee Society Score obtained during telephone interviews with patients, was used as the evaluation 
tool.
Results: On the tKSS-A (telephone Knee Society Score-A), the score improved from 43.52 ± 20.20 to 89.71 ± 13.69 (P < 
0.05), and on the tKSS-B (telephone Knee Society Score-B), the score improved from 50.66 ± 20.05 to 89.38 ± 15.76 (P < 
0.05). The total improvement was from 94.18 ± 31.43 to 179.10 ± 24.69 (P < 0.05).
Conclusion: Gel-type autologous chondrocyte implantation for chondral knee defects appears to be a safe and 
effective method for both decreasing pain and improving knee function.
Background
As articular cartilage has only limited ability to regener-
ate, many treatment modalities have been developed dur-
ing the past several decades to treat symptomatic
articular cartilage injuries [1]. Among these treatment
modalities, autologous chondrocyte implantation (ACI)
has become a standard technique used to repair symp-
tomatic, full-thickness, chondral injuries [2-4].
The traditional ACI technique involves injection of cul-
tured autologous cartilage cells into the prepared carti-
lage defect which is covered by a periosteal flap. The
technique requires extensive surgical exposure in order
for the sutures to be watertight as well as an additional
incision for harvesting the periosteum. In addition, cell
leakage, graft detachment, and graft hypertrophy are rec-
ognized as potential problems [5].
To solve the periosteum-associated problems, many
biomaterials have also been used for a new generation of
ACI techniques in which cells are combined with bioac-
tive, resorbable biomaterials such as collagen membrance
[6], hyaluronan polymer [7], and copolymers of polylactin
and polyglactin [8]. Using this method, the necessity of a
second incision to harvest tibial periosteum can be
avoided and the surgery time can be shortened. ACI
using a collagen matrix is currently used as a membrane
on which chondrocytes are seeded and cultured for sev-
eral days before the membrane is cut to the correct size
and shape of the defect. Although this technique has
advantages over conventional ACI due to its simplicity
and the fact that it does not use periosteum, there are
some potential disadvantages regarding cell loss and
detachment of the membrane.
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not cover the total condyle so that it is watertight in an
arthritic knee, and there is also a high risk of breakdown
of the treated lesion and its subsequent progression to
arthritis. In addition, the technique using collagen mem-
brane has similar risks when treating a large lesion as
those noted with the total condyle.
We have developed a new technique that reduces the
surgical difficulties and facilitates the attachment and
even distribution of chondrocytes in a defect. This
method is based on the transplantation of in vitro cul-
tured autologous chondrocytes mixed with fibrin glue
into a cartilage defect.
For several years we have used gel-type autologous
chondrocyte (Chondron™) implantation without using
periosteum or membrane. Our current study involved
evaluation of the clinical results of gel-type ACI (GACI)
at many clinical centers and at various time points during
the postoperative follow-up.
Methods
Data from 98 patients who underwent gel-type ACI
(GACI) at ten Korean hospitals between January 2005
and November 2008, were included and were divided into
two groups according to the length of the follow-up
period, i.e. 13~24-month follow-up and greater than 25-
month follow-up.
Institutional review board (Catholic University of
Korea) approval was obtained for this study. Patient
informed consent was not required by the institutional
review board.
Among the 98 study patients, there were 54 males
(55.1%), and 44 females (44.9%). Patient age ranged from
17 to 65 years (mean age = 43.72 years, SD = 9.10). The
average defect size was 5.23 ± 2.70 cm2 (range: 1.00 ~
14.50 cm2), i.e. less than 4 cm2 in 29 patients (29.6%),
4.0~7.9 cm2 in 57 patients (58.2%), and greater than 8.0
cm2 in 12 patients (12.2%). The average follow-up period
was 24.35 ± 8.35 months (range: 13 ~ 52 months) with a
13~24-month follow-up in 58 patients (59.2%) and
greater than a 25-month follow-up in 40 patients (40.8%)
(Table 1).
Evaluation of patient suitability for study participation 
(inclusion and exclusion criteria)
The indications for ACI were clinically significant, symp-
tomatic, cartilaginous defects (Outerbrige III-IV) of the
knee joint in patients with one or more cartilage defects
not exceeding 15 cm2 for a single defect or 20 cm2 for
multiple defects. The knee joint must be stable and with-
out a severe deformity greater than 5 to 10 degrees of the
valgus or varus.
The exclusion criteria included advanced osteoarthritis
(Kellgren-Lawrence Grading Scale >2) and inflammatory
arthritis with severe deformity exceeding the above
range. Patellofemoral instability, drug abuse history, and
psychological problems were also included as patient
exclusion criteria.
Surgical techniques
We used a two-stage surgical technique. After completing
the clinical and radiological assessments, arthroscopy
was performed in order to measure the positions, sizes,
and depths of the chondral defects and to identify chon-
dral defects and abnormalities involving the menisci and
ligaments. Knee standing AP, lateral, and tangential
radiographs were obtained to evaluate the knee joint
deformity and the potential presence of osteoarthritis. In
addition, 200-300 mg of cartilage from a non-weight-
bearing portion of the knee, generally the medial or lat-
eral superior ridge of the condyle or the intercondylar
notch, was collected and sent to the GMP-certified, cell-
culturing facility (SewonCellontech, Korea) for process-
ing using the CE/MDD-certified, human-cell-processing
kit (CRM kit™, SewonCellontech, Korea).
Autologous chondrocyte implantation was performed
when 1.2 × 107 chondrocytes/vial had been cultured for 4
~ 6 weeks after the initial surgery. Autologous chondro-
cytes were aseptically processed. The cell viabilities of all
supplied products were greater than 80% prior to the final
packaging.
During the second surgical procedure, arthrotomy was
performed on the medial or lateral portion of the patella
along the chondral defects. To ensure that the implanted
chondrocytes merged well with normal cartilaginous tis-
sue when exposed to defective areas, damaged cartilage
was removed from the edges of the chondral defects.
Multiple holes of 5-mm depth and 2.5-mm diameter were
made at 1-2-cm intervals using a 2.5-mm drill bit so that
the holes of the defect would receive the holding force of
the graft (Fig. 1a). After release of the tourniquet, bone
bleeding control was achieved using compression force
applied to the holes using epinephrine-soaked gauze
packing. For the injection procedure, two, 1-ml syringes
and a Y-shaped mixing adapter were used. In one syringe,
1 ml of fibrinogen (Greenplast, Greencross, Korea) was
filled with medium (CRM kit™, SewonCellontech, Korea),
and the other syringe was filled with 0.9 ml of cell suspen-
sion and 0.1 ml of thrombin. Cultured autologous chon-
drocytes mixed with fibrin (1:1) were then slowly injected
into the defect area (Fig. 1b).
In order not to overflow the margin, the dependent
position of the defect site was maintained for five min-
utes. Flexion and extension motion of the knee was per-
formed three to five times in order to check for any graft
failure. The wound was then closed layer by layer. Use of
continuous passive motion (CPM) machines was recom-
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weight bearing beginning 6~8 weeks postoperatively.
Patient evaluations
Details concerning our patients' clinical outcomes were
collected with the telephone score format initially used to
estimate the KSS (Fig. 2)[9]. Recorded items included
patient demographics, defect size, defect location, and
the number of vials of chondrocyte used for implantation.
The above information was obtained before implantation
and again during telephone follow-up after post-implan-
tation.
Our clinicians rated the patient knee status using the
standardized 100-point rating scale of the telephone
Knee Society Scoring system (tKSS) regarding pain (A)
and function (B) (Fig. 2). Adverse event data were col-
lected and included in the analysis regardless of whether
or not they were considered to be related to the ACI.
Statistical analysis
Categorical variables are presented as numbers and per-
centages, and continuous variables are expressed as mean
± SD and range. The improvements of tKSS-A and B
scores were analyzed using either the paired t test or the
Wilcoxon signed rank sum test, as indicated. To deter-
mine whether improvements were related to age, gender,
defect size, defect location, the number of vials of chon-
drocyte used for implantation or the time interval
between cartilage harvesting and ACI, we used the
Mann-Whitney U test, Kruskal Wallis test, and Spear-
man's rho. All reported p-values were two-sided, and a p-
value < 0.05 was considered statistically significant. SPSS
software version 11.5 (SPSS Inc, USA) was used for statis-
tical analyses.
Cell and gel mixture ex-vivo evaluation
Fibrin-glue was used to develop the implantation proto-
col of gel-type cultured autologous chondrocytes. The
order and ratio of mixing the major constituents of the
fibrin glue with the cultured autologous chondrocytes,
were optimized in order to guarantee maximal cellular
Table 1: Patient Description
Gender Male n (%) 54 (55.1%)
Female n (%) 44 (44.9%)
Age (years) Mean ± std (Min ~ Max) 43.72 ± 9.10 (17 ~ 65)
<30 years n (%) 10 (10.2%)
30~39 years n (%) 12 (12.2%)
40~49 years n (%) 53 (54.1%)
> = 50 years n (%) 23 (23.5%)
Defect location Femoral condyle n (%) 83 (84.7%)
Other n (%) 15 (15.3%)
Defect Size (cm2) Mean ± std (Min ~ Max) 5.23 ± 2.70 (1.00 ~ 14.50)
< 4.0 cm2 n (%) 29 (29.6%)
4.0~7.9 cm2 n (%) 57 (58.2%)
>8.0 cm2 n (%) 12 (12.2%)
F/u period (Months) Mean ± std (Min ~ Max) 24.35 ± 8.35 (12~ 52)
13~24 Months n (%) 58 (59.2%)
25 Months~ n (%) 40 (40.8%)
Figure 1 The gel-type ACI (Chondron™) surgery. a) Preparation of 
cartilage lesion, b) After injection of cell gel mixture, C) MRI one year 
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length of time after implantation.
To measure the viability of chondrocytes mixed with
fibrin according to the established protocol, cultured
human chondrocytes (1.2 × 107cells/vial) proliferated ex
vivo, were collected. The collected cell suspension was
mixed with the same volume of fibrin glue used to pre-
pare 2 ml of cell-fibrin mixture gel. This gel was cultured
for three days at 37°C in an 8% CO2 incubator. The viabil-
ity of chondrocytes within the fibrin gel which was cul-
tured for 0, 12, 24, 48, and 72 hours, was measured using
MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide, Sigma, USA.) assay.
In addition, the viable status of chondrocytes within the
cell-fibrin matrix was grossly examined using Calcein-
AM/Ethidium homodimer-1 (Invitrogen, USA) staining.
Live cells were expressed as a green color and dead cells
were expressed as a red color under fluorescent micros-
copy following the staining. A scanning electron micro-
scope (Hitachi, Japan) was used to confirm the
morphological structure of the mixture of chondrocytes
and fibrin. The material safety of autologous chondro-
cytes mixed with fibrin was confirmed as lacking the tox-
icity seen in a subcutaneous toxicity study using C57BL/6
mice (Korea Institute of Toxicology, 2006).
Results
The MTT assay showed that the viability of the cells in
the gel remained above 90% of the initial viability for 72
hours (Fig. 3a). The cells were found to be well mixed
with fibrin and evenly distributed within the gel (Fig. 3b).
The viable status and distribution of chondrocytes in the
Figure 2 The telephone score format used to estimate the KSS.
Choi et al. BMC Musculoskeletal Disorders 2010, 11:103
http://www.biomedcentral.com/1471-2474/11/103
Page 5 of 8gel were also confirmed based on the Calcein-AM/Ethid-
ium homodimer-1 staining. The viability of the cells in
the cell-gel mixture, according to the fluorescence stain-
ing, was found to exceed 90% after 72 hours of culturing
the mixture, as shown in the MTT assay (Fig. 4). We
found that the pores were evenly present within the fibrin
gel. We was also noted that the chondrocytes were evenly
distributed and maintained a round shape within the
pores on the scanning electron microscopy (SEM) (Fig 5).
Clinician evaluations showed significant mean
improvement in the tKSS-A and tKSS-B scores for the all
of the data of the three, postoperative, follow-up periods
(95% confidence interval, P-value < 0.05) (Fig. 6).
The tKSS-A score showed improvement from 43.52 ±
20.20 to 89.71 ± 13.69 (P < 0.05), while according to the
tKSS-B scores, knees were shown to have improved from
50.66 ± 20.05 to 89.38 ± 15.76 (P < 0.05). The total
improvement was from 94.18 ± 31.43 to 179.10 ± 24.69 (P
< 0.05). Clinical evaluations showed significant mean
improvement in the tKSS-A and tKSS-B scores for each
postoperative follow-up period (95% confidence interval,
P-value < 0.05) (Table 2).
According to the follow-up period, improvement of the
score of the 'greater than 25 months' group was statisti-
cally greater than that of the other group (Table 3).
Improvements in tKSS-A and B scores were not found to
be related to age, gender, defect size, defect location, the
number of vials of chondrocyte used for implantation or
the time interval between cartilage harvesting and ACI.
Adverse events
One patient required repeat surgery five months postop-
eratively when another cartilage defect was noticed by the
surgeon. The amount of improvement in this patient was
40 points total (tKSS-A : 30, tKSS-B : 10) 15 months post-
operatively.
Adverse events related to GACI occurred in 2.04% (2/
98) of the study patients and were caused by the 'catching
symptom'. These 'catching with pain' symptoms subsided
postoperatively after they were put on NSAID (Non-Ste-
roidal Anti-Inflammatory Drug) medication.
Figure 5 A scanning electron microscopy picture showing the 
morphological structure of chondrocytes within the cell-fibrin 
gel. The cell-fibrin gel was incubated in a CO2 incubator and was 
freeze-dried in order to reveal the scaffold structure. a) ×500, b) ×3000.
a b
Figure 4 The viable chondrocytes within the cell-gel mixture on 
Calcein-AM/Ethidium homodimer-1 staining: a) A 0-hour and b) A 
72-hour culture (×100). The white arrow in b) denotes the dead cells 
which appear as a reddish color.
a b
Figure 3 The viability and distribution of chondrocytes within the cell-fibrin gel. a) The relative cell viability profiles assayed by MTT assay. b) 
The distribution of chondrocytes within the gel.
a b
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The surgical procedure of conventional ACI can be sum-
marized as consisting of debridement of the cartilage
defect, harvesting of periosteum, suturing the perios-
teum, and chondrocyte implantation [10]. Among these
procedures, periosteum suturing is a difficult and time-
consuming procedure for the surgeon, and periosteal har-
vesting and periosteum suturing procedures have some
risk of patient morbidity. Conventional ACI is not pre-
ferred because of the periosteal grafting component
which requires an additional operation to harvest the
periosteum. In addition, for water-tight suturing of the
periosteal graft to the surrounding cartilage, a large surgi-
cal incision is required, thus presenting the potential
problem of subsequent leakage of injected cells from the
defect as well as graft detachment [11].
To overcome these potential problems, some research-
ers have proposed using collagen membrane rather than
periosteum [5,11,12]. If the surgeon's preference is to not
use periosteum, methods using collagen membrane can
eliminate the need for a second incision for periosteal
harvest as well as reducing the long surgical time and
extensive suturing. However, with this approach there are
also some potential problems such as the loss of critical
chondrocytes caused by the cutting and repeated manip-
ulation of the seeded membrane. There is also the possi-
bility of detachment of the collagen membrane from the
cartilage defect. Therefore, it is becoming increasingly
evident that it is necessary to develop a new method.
In the gel-type ACI (GACI), the fibrin can already
maintain the shape of the articulation approximately five
minutes after injection, thus allowing the cells to remain
at the injected sites. And even if there is a defect along the
chondral margin, fibrin helps to maintain the shape of the
graft according to the articulation [13]. The 5-mm-deep
holes serve an important function by increasing the adhe-
sive force of the graft to the defect during knee motion. In
the surgical procedures, in order to prevent both the for-














































































Table 2: Overall KSS scores
Pre-op Post-op p-value1)
(Mean ± std) (Mean ± std)
tKSS-A 43.52 ± 20.20 89.71 ± 13.69 <0.05
tKSS-B 50.66 ± 20.05 89.38 ± 15.76 <0.05
tKSS-total 94.18 ± 31.43 179.10 ± 24.69 <0.05
Post-op 13~24 months tKSS-A 47.37 ± 20.56 88.58 ± 15.04 <0.05
tKSS-B 53.70 ± 18.62 88.70 ± 16.39 <0.05
tKSS-total 101.08 ± 30.22 177.29 ± 27.19 <0.05
Post-op > 25 months tKSS-A 37.92 ± 18.53 91.35 ± 11.44 <0.05
tKSS-B 46.25 ± 21.44 90.37 ± 14.95 <0.05
tKSS-total 84.17 ± 30.78 181.72 ± 20.57 <0.05
1) Statistical significance was evaluated using the Wilcoxon signed rank test sign test.
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of the injected cell and fibrin mixture, bleeding control is
very important. Fortunately, fibrin sealants are biological
adhesives that mimic the final step of the coagulation cas-
cade and therefore help with the bone bleeding control
[15]. Also, any commercially available fibrin product can
be used because of the similar range of the amounts of
fibrinogen and thrombin. Following surgery, we check the
stability of the graft by flexion and extension knee-
motion exercise. If the graft adequately remains in the
defect site, we finish the surgery.
The number of cells introduced in initial explants is
important as the seeded chondrocyte number is linearly
related to biosynthetic activity [16]. In that respect, GACI
can have an advantage over other treatments such as
ACI-C and MACI. Collagen membrane occupies quite a
substantial amount of space in a cartilage defect,
although the cell-gel mixture occupies the space in the
GACI. Although the optimal number of required cells has
not been determined, high cell densities seem to be desir-
able [17] and one vial of Chondron™ could cover a total
condyle defect. The 96 patients (98.0%) we treated
achieved measurable postoperative improvement and
only two patients (2.0%) showed deterioration of their 'no
change'. One patient required repeat surgery, and all of
the patients who underwent surgery showed substantial
improvement during the follow-up period. The authors
regard these as encouraging results compared with those
of other reports regarding marrow stimulation or ACI
[18]. In fact, our repeat surgery rate is far less than that
associated with other forms of knee surgery [19,20].
However, it is difficult to conclude that this technique is
superior to other techniques, such as ACI-C or MACI, as
this study is not a comparative study. Many successful
results have also been reported using other techniques
[6,21,22]. In this study, the authors used a telephone-
based scoring system. If the patient does not feel any dis-
comfort, he/she would not need to come to the hospital
as job and time limitations frequently prevent patients
from checking in with their doctors. Therefore, the
necessity and benefits of telephone or internet consulta-
tion are increasing. There is also a continuing necessity to
develop a new, remote scoring system which can handle
the other knee condition evaluations.
Swedish researchers have reported improvements for
longer than two years following ACI [23]; similarly, in our
study, improvements were more apparent after 24
months. However, the preoperative score of greater than
25-month follow-up group was lower than that of 13~24-
month follow-up group. Therefore, it is difficult to insist
the same result as Swedish report.
An even more positive aspect of this study is that clini-
cal improvement was apparent even during the short-
term, post-op follow-up period of less than two years fol-
lowing surgery.
With respect to the surgical success based on the size of
the articular cartilage defects, there was no statistical dif-
ference in the results. There was one case of 1 cm2 of car-
tilage defect and the others were over 2 cm2. A small
cartilage defect can cause severe discomfort and pain if a
patient's activity level is high. The pressure generated
during weight-bearing is so high that it stimulates a weak
articular cartilage area even though the defect size may
be very small. Therefore, covering a cartilage defect with
healthy cartilage is very important, and GACI offers a
successful treatment option for both small and large car-
tilage defects.
Conclusion
GACI used to repair of articular cartilage defects of the
knee appears to be a safe and effective method for restor-
ing patient knee function.
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